n=1225 (telehealthcare: n=578; usual care n=647) | Between-group difference (95% CI) or ICER | Intraclass coefficient |
Base-case analysis | ||
QALY (unadjusted mean difference)* | 0.0062 (−0.0307; 0.0431) | 0.007 |
Costs (unadjusted mean difference)* | 1219 (−937; 3376) | 0.014 |
QALY (adjusted mean difference)† | 0.0132 (−0.0083; 0.0346) | 0.000 |
Costs (€) (adjusted mean difference)‡ | 728 (−754; 2211) | 0.014 |
ICER (adjusted, € per QALY) | 55 327 | |
Sensitivity analysis 1: all-cause hospital contacts | ||
Costs (€) (adjusted mean difference)‡ | 583 (−1397; 2563) | 0.005 |
ICER (adjusted, € per QALY) | 44 301 | |
Sensitivity analysis 2: reduced procurement prices and larger scale | ||
Costs (€) (adjusted mean difference)‡ | 618 (−865; 2100) | 0.014 |
ICER (adjusted, € per QALY) | 46 931 | |
Sensitivity analysis 3: reduced monitoring time | ||
Costs (€) (adjusted mean difference)‡ | 525 (−969; 2018) | 0.012 |
ICER (adjusted, € per QALY) | 39 854 | |
Sensitivity analysis 1+2+3: most optimistic scenario | ||
Costs (€) (adjusted mean difference)‡ | 277 (−1700; 2255) | 0.014 |
ICER (adjusted, € per QALY) | 21 068 |
*Linear mixed model with treatment arm as only covariate.
†Linear mixed model adjusted for treatment arm, baseline EQ5D score, age, gender, baseline FEV1%, marital status, presence of diabetes, presence of cancer and clustering.
‡Linear mixed model adjusted for treatment arm, baseline EQ5D score, baseline costs, age, baseline FEV1%, presence of musculoskeletal and clustering.
QALY, quality-adjusted life-year; ICER, incremental cost-effectiveness ratio.